MONTREAL--(BUSINESS WIRE)--Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB) through LRP-1 targeting, announced today that complete phase 1/2 clinical data in two clinical studies of its lead oncology program, ANG1005, for the treatment of brain cancers, including glioblastoma (GBM) and brain metastases, were presented at the 2010 American Society for Clinical Oncology (ASCO) Annual Meeting, June 4-8, in Chicago, IL. These data demonstrated that by targeting the lipoprotein receptor-related protein (LRP-1), which is highly expressed on the surface of the blood-brain barrier (BBB) and upregulated on malignant cancer cells. Angiochem’s novel anticancer agent, ANG1005, gained entry into the brain and penetrated tumor cells to provide increased time to disease progression, significant reductions in tumor size and reversal of neurological deficits caused by tumor intrusion.
